Dr Louise Emmett

Conjoint Professor

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Auckland	BSc(HONS)	1989	Medicine
University of Auckland	MBChB	1991	Medicine
Royal North Shore Hospital, Australia		1992-1996	Internship, General Medicine/Surgery
The Royal Australasian College of Physicians, Australia	FRACP	1996-1999	Medical Residency, Medicine
Toronto Western Hospital, Toronto, Canada		2000-2001	Nuclear medicine Fellow
Staff Specialist Nuclear Medicine, Concord Hospital, Sydney	FAANMS	2001-2012
Auckland University	MD	2014 completed	Thesis in Nuclear Cardiology

Medicine & Health

School of Clinical Medicine

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Auckland	BSc(HONS)	1989	Medicine
University of Auckland	MBChB	1991	Medicine
Royal North Shore Hospital, Australia		1992-1996	Internship, General Medicine/Surgery
The Royal Australasian College of Physicians, Australia	FRACP	1996-1999	Medical Residency, Medicine
Toronto Western Hospital, Toronto, Canada		2000-2001	Nuclear medicine Fellow
Staff Specialist Nuclear Medicine, Concord Hospital, Sydney	FAANMS	2001-2012
Auckland University	MD	2014 completed	Thesis in Nuclear Cardiology

A. Personal Statement

The advent of small molecule peptide imaging and therapy is changing the face of oncology diagnosis, prognosis and treatment. This has had a dramatic effect in prostate cancer, with a paradigm shift in clinical practice. At the forefront of this shift in clinical practice, St Vincent’s commenced multiple imaging and therapy trials in prostate cancer using GaPSMA PET and LuPSMA therapy between 2014 and 2018. Having made the move from Nuclear Cardiology in 2012 (culminating in an MD based on publications in the field), to theranostics was a personal paradigm shift in focus that co-incided with the disruptive technology taking place. It has been an incredible opportunity to explore a new weapon in the armament against cancer, well before the rest of the world.

Our prospective trials in LuPSMA therapy, into the diagnostic and prognostic value of PSMA PET and into the manipulability of the PSMA receptor in response to androgen blockade, have been practice changing

E-mail

l.emmett@unsw.edu.au

Book Chapters | 2022

Emmett L, 2022, 'Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA)', in Nuclear Medicine and Molecular Imaging: Volume 1-4, Elsevier, pp. 214 - 219, http://dx.doi.org/10.1016/B978-0-12-822960-6.00150-2

Book Chapters | 2011

Wong T; Girgis CM; Ngu MC; Chen RCY; Emmett L; Archer KA; Seibel MJ, 2011, '13. A 40-year-old Man with Widespread Bone Pain', in Diagnostic Dilemmas: Images in Endocrinology, The Endocrine Society, pp. 74 - 78, http://dx.doi.org/10.1210/dde1.9781936704583.ch13

Book Chapters | 2004

Emmett L, 2004, 'Vascular Manifestations. Chapter 48.', in Nuclear medicine in clinical diagnosis and treatment., pp. 693 - 707
Journal articles | 2023

Buteau JP; Moon D; Fahey MT; Roberts M; Thompson J; Murphy DG; Papa N; Mitchell C; Kasivisvanathan V; Stricker P; O'Brien J; Counter W; Sharma G; Agrawal S; Ho B; Yeung T; De Abreu Lourenço R; Dhillon HM; Hofman MS; Emmett L, 2023, 'PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [⁶⁸Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.', Journal of Clinical Oncology, 41, pp. TPS397 - TPS397, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps397

Journal articles | 2023

Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L, 2023, 'Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer', BJU International, 131, pp. 588 - 595, http://dx.doi.org/10.1111/bju.15929

Journal articles | 2023

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, pp. 17588359231156392, http://dx.doi.org/10.1177/17588359231156392

Journal articles | 2023

Emmett L; Wong V; Lenzo N; Lengyelova E; Biggin C, 2023, 'Positron emission tomography of patients with confirmed prostate cancer using ⁶⁴Cu-SAR-bisPSMA.', Journal of Clinical Oncology, 41, pp. 318 - 318, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.318

Journal articles | 2023

Feldman DR; Tran B; Emmett L; Hofman MS; Olivier P; Mahammedi H; Galetic I; Pokorska-Bocci A; Bouisset F; Gollmer K; Pavlyuk M; Tauchmanova L; Herrmann K, 2023, 'First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.', Journal of Clinical Oncology, 41, pp. TPS3160 - TPS3160, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3160

Journal articles | 2023

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256

Journal articles | 2023

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Journal articles | 2023

Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G, 2023, 'Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium–Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes', International Journal of Radiation Oncology Biology Physics, 115, pp. 106 - 117, http://dx.doi.org/10.1016/j.ijrobp.2022.05.044

Journal articles | 2023

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Journal articles | 2023

Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D, 2023, 'A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy', European Urology Open Science, 53, pp. 90 - 97, http://dx.doi.org/10.1016/j.euros.2023.05.002

Journal articles | 2023

Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K, 2023, 'Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2830 - 2845, http://dx.doi.org/10.1007/s00259-023-06255-8

Journal articles | 2023

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Journal articles | 2023

Lengyelova E; Wong V; Lenzo N; Parker M; Emmett L, 2023, '⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.', Journal of Clinical Oncology, 41, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5039

Journal articles | 2023

Mei R; Kessler L; Pabst KM; Weber M; Schmidkonz C; Rischpler C; Zacho HD; Hope T; Schwarzenbock SM; Allen-Auerbach M; Emmett L; Ferdinandus J; Unterrainer M; Schaarschmidt BM; Umutlu L; Farolfi A; Castellucci P; Nanni C; Telo S; Fanti S; Herrmann K; Fendler WP, 2023, '⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study', Journal of Nuclear Medicine, 64, pp. 1043 - 1048, http://dx.doi.org/10.2967/jnumed.122.265245

Journal articles | 2023

Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G, 2023, 'Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer', Radiation Oncology, 18, pp. 127, http://dx.doi.org/10.1186/s13014-023-02302-8

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

Journal articles | 2023

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Journal articles | 2023

Pouliot F; Emmett L, 2023, 'Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now', European Urology, http://dx.doi.org/10.1016/j.eururo.2023.07.007

Journal articles | 2023

Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RDA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) , 2023, 'DIPPER trial protocol: A multi-centre, randomised trial of salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy (ANZUP 2002).', BJU Int, http://dx.doi.org/10.1111/bju.16158

Journal articles | 2023

Roberts MJ; Hruby G; Kneebone A; Martin JM; Williams SG; Frydenberg M; Murphy DG; Namdarian B; Yaxley JW; Hofman MS; Davis ID; Emmett L, 2023, 'Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky?', BJU International, 132, pp. 146 - 148, http://dx.doi.org/10.1111/bju.16086

Journal articles | 2023

Roberts MJ; Maurer T; Perera M; Eiber M; Hope TA; Ost P; Siva S; Hofman MS; Murphy DG; Emmett L; Fendler WP, 2023, 'Using PSMA imaging for prognostication in localized and advanced prostate cancer', Nature Reviews Urology, 20, pp. 23 - 47, http://dx.doi.org/10.1038/s41585-022-00670-6

Journal articles | 2023

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Journal articles | 2023

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Lee ST; Weickhardt AJ; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271

Journal articles | 2023

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2023, 'Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study', Radiotherapy and Oncology, 184, http://dx.doi.org/10.1016/j.radonc.2023.109678

Journal articles | 2023

Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M, 2023, 'Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)', European Urology, 83, pp. 405 - 412, http://dx.doi.org/10.1016/j.eururo.2023.02.002

Journal articles | 2023

Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C, 2023, 'PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2529 - 2536, http://dx.doi.org/10.1007/s00259-023-06185-5

Journal articles | 2023

Soon YY; Marschner I; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2023, 'Effects of [¹⁷⁷Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.', Journal of Clinical Oncology, 41, pp. 5045 - 5045, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5045

Journal articles | 2023

Swiha M; Ayati N; Oprea-Lager DE; Ceci F; Emmett L, 2023, 'How to Report PSMA PET', Seminars in Nuclear Medicine, http://dx.doi.org/10.1053/j.semnuclmed.2023.07.007

Journal articles | 2023

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne H; Tunariu N; Ho B; Young S; Singbo MNU; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial', Cancer Imaging, 23, http://dx.doi.org/10.1186/s40644-023-00570-x

Journal articles | 2023

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne HA; Tunariu N; Ho B; Young S; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.', Journal of Clinical Oncology, 41, pp. 316 - 316, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.316

Journal articles | 2023

Unterrainer L; Farolfi A; Rosar F; Denis CS; Emmett L; de Kouchkovsky I; Hope TA; Hotta M; Gafita A; Djaileb L; Czernin J; Calais J, 2023, 'Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.', Journal of Clinical Oncology, 41, pp. 5063 - 5063, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5063

Journal articles | 2023

Vis AN; Meijer D; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Heymans MW; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Stricker P; Haynes A-M; Oprea-Lager DE; Coughlin GD; van Leeuwen PJ, 2023, 'Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography.', Eur Urol Oncol, http://dx.doi.org/10.1016/j.euo.2023.03.010

Journal articles | 2023

Zamboglou C; Arnoux A; Janbain A; Strouthos I; Farolfi A; Koerber S; Peeken J; Vogel M; Ferentinos K; Shelan M; Grosu AL; Kroeze S; Guckenberger M; Fanti S; Hruby G; Scharl S; Wiegel T; Henkeberens C; Emmett L; Hegemann N-S, 2023, 'Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy in recurrent prostate cancer.', Journal of Clinical Oncology, 41, pp. 355 - 355, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.355

Journal articles | 2023

Zamboglou C; Ferentinos K; Arnoux A; Janbain A; Strouthose I; Farolfi A; Koerber S; Peeken J; Vogel M; Vrachimis A; Spohn SKB; Shelan M; Grosu A; Kroeze S; Guckenberger M; Fanti SF; Belka C; Hruby G; Scharl S; Wiegel T; Henkenberens C; Emmett L; Schmidt-Hegemann NS, 2023, 'OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer', Radiotherapy and Oncology, 182, pp. S335 - S336, http://dx.doi.org/10.1016/s0167-8140(23)08607-3

Journal articles | 2023

Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS, 2023, 'Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer', JAMA network open, 6, pp. e2314748, http://dx.doi.org/10.1001/jamanetworkopen.2023.14748

Journal articles | 2022

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS; Akhurst T; Alipour R; Banks P; Beaulieu A; Chua W; Dhiantravan N; Ford K; Gedye C; Goh JC; Guminski A; Hamid A; Haskali MB; Hicks RJ; Hsiao E; Kirkwood ID; Kong G; Kwan EM; Langford A; Lawrence N; Lewin J; Lin P; McDonald W; Moodie K; Murphy DG; Ng S; Pattison DA; Pokorski I; Ramdave S; Ravi Kumar AS; Redfern AD; Rutherford NK; Saghebi J; Spain L; Subramaniam S; Tan TH; Thang SP; Tran B; Wallace R; Weickhardt A; Yip S, 2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2

Journal articles | 2022

Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL, 2022, 'The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma', Annals of Surgical Oncology, 29, pp. 2871 - 2881, http://dx.doi.org/10.1245/s10434-021-11231-3

Journal articles | 2022

Dimitriou F; Lo SN; Tan AC; Emmett L; Kapoor R; Carlino MS; Long GV; Menzies AM, 2022, 'FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 33, pp. 99 - 106, http://dx.doi.org/10.1016/j.annonc.2021.10.003

Journal articles | 2022

Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS, 2022, 'The PRIMARY Score: Using Intraprostatic ⁶⁸Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63, pp. 1644 - 1650, http://dx.doi.org/10.2967/jnumed.121.263448

Journal articles | 2022

Emmett L; Pattison DA; Roberts MJ, 2022, 'All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others', European urology oncology, 5, pp. 283 - 284, http://dx.doi.org/10.1016/j.euo.2022.04.002

Journal articles | 2022

Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A, 2022, 'EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy', European urology oncology, 5, pp. 530 - 536, http://dx.doi.org/10.1016/j.euo.2022.05.003

Journal articles | 2022

Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD, 2022, 'Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63, pp. 1659 - 1664, http://dx.doi.org/10.2967/jnumed.121.263743

Journal articles | 2022

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG, 2022, 'Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study', Journal of Nuclear Medicine, 63, pp. 1531 - 1536, http://dx.doi.org/10.2967/jnumed.121.263139

Journal articles | 2022

Lee ST; Emmett LM; Pattison DA; Hofman MS; Bailey DL; Latter MJ; Francis RJ; Scott AM, 2022, 'The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective', Journal of Nuclear Medicine, 63, pp. 819 - 822, http://dx.doi.org/10.2967/JNUMED.122.263996

Journal articles | 2022

Liu W; Fakir H; Randhawa G; Alfano R; Corkum M; Kassam Z; Rachinsky I; Chung HT; Chung P; Loblaw A; Morton G; Sexton T; Kapoor A; Ward A; Zukotynski K; Emmett L; Bauman G, 2022, 'Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI', Clinical and Translational Radiation Oncology, 32, pp. 41 - 47, http://dx.doi.org/10.1016/j.ctro.2021.11.006

Journal articles | 2022

Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L, 2022, 'Diagnostic value of ⁶⁸Ga-DOTATATE PET-CT imaging for staging of ER⁺/PR⁺ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and ¹⁸F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342

Journal articles | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Journal articles | 2022

Pomykala KL; Herrmann K; Emmett L; Lalumera E; Fanti S, 2022, 'Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?', European Urology Open Science, 44, pp. 11 - 12, http://dx.doi.org/10.1016/j.euros.2022.07.015

Journal articles | 2022

Ptasznik G; Papa N; Kelly BD; Thompson J; Stricker P; Roberts MJ; Hofman MS; Buteau J; Murphy DG; Emmett L; Moon D, 2022, 'High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer', BJU International, 130, pp. 5 - 7, http://dx.doi.org/10.1111/bju.15736

Journal articles | 2022

Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L, 2022, 'Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups', BJU International, 130, pp. 32 - 39, http://dx.doi.org/10.1111/bju.15762

Journal articles | 2022

Roberts MJ; Emmett L, 2022, 'EDITORIAL COMMENT', Journal of Urology, 207, pp. 348 - 349, http://dx.doi.org/10.1097/JU.0000000000002254.01

Journal articles | 2022

Roberts MJ; Morton A; Papa N; Franklin A; Raveenthiran S; Yaxley WJ; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Emmett L; Yaxley JW, 2022, 'Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 49, pp. 3289 - 3294, http://dx.doi.org/10.1007/s00259-022-05756-2

Journal articles | 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, pp. 772 - 772, http://dx.doi.org/10.3390/ph15070772

Journal articles | 2022

van Leeuwen PJ; Emmett L, 2022, '¹⁸F-PSMA-11 as an Attractive ⁶⁸Ga-PSMA-11 Alternative for Prostate Cancer Imaging', European Urology, 82, pp. 510 - 511, http://dx.doi.org/10.1016/j.eururo.2022.06.001

Journal articles | 2021

Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N, 2021, 'Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer', Future Oncology, 17, pp. 2225 - 2241, http://dx.doi.org/10.2217/fon-2020-1293

Journal articles | 2021

Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K, 2021, 'E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 1626 - 1638, http://dx.doi.org/10.1007/s00259-021-05245-y

Journal articles | 2021

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Journal articles | 2021

De Bono J; Delaney E; Emmett L; Florisson D; Ghani M; Kemp S; Smith J, 2021, 'M13 Cardiac Surgery Advanced Life Support – A Unique Approach and Learning Program', Heart, Lung and Circulation, 30, pp. S6 - S7, http://dx.doi.org/10.1016/j.hlc.2021.03.022

Journal articles | 2021

Dhiantravan N; Emmett L; Joshua AM; Pattison DA; Francis RJ; Williams S; Sandhu S; Davis ID; Vela I; Neha N; Bressel M; Murphy DG; Hofman MS; Azad AA, 2021, 'UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342, http://dx.doi.org/10.1111/bju.15384

Journal articles | 2021

Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P, 2021, 'The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study[Formula presented]', European Urology, 80, pp. 682 - 689, http://dx.doi.org/10.1016/j.eururo.2021.08.002

Journal articles | 2021

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Journal articles | 2021

Ende J; Amin A; Sheehan-Dare G; Cusick T; Ho B; Keane J; Nguyen A; Liu V; Lee J; Chan L; Chen A; Fullard K; Stricker P; Emmett L, 2021, 'Pilot Trial Comparing the Performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/ CT in the Detection of Prostate Cancer Recurrence in Men with Rising PSA Following Radical Prostatectomy', Journal of Radiology and Medical Imaging, https://meddocsonline.org/journal-of-radiology-and-medical-imaging/pilot-trial-comparing-the-performance-of-68Ga-PSMA-11-PET-CT-to-18F-PSMA-1007-PET-CT-in-the-detection-of-prostate-cancer-recurrence-in-men-with-rising-PSA-following-radical-prostatectomy.pdf

Journal articles | 2021

Fendler WP; Calais J; Eiber M; Simko JP; Kurhanewicz J; Santos RD; Feng FY; Reiter RE; Rettig MB; Nickols NG; Kishan AU; Shozo O; Emmett L; Zacho HD; Ilhan H; Rischpler C; Wetter A; Schoder H; Burger IA; Slavik R; Carroll PR; Lawhn-Heath C; Herrmann K; Czernin J; Hope TA, 2021, 'False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 501 - 508, http://dx.doi.org/10.1007/s00259-020-04945-1

Journal articles | 2021

Gondoputro W; Blazevski A; Amin A; Scheltema M; Agrawal S; Cusick T; Van Leeuwen P; Van Leeuwen F; Emmett L; Thompson J; Stricker P, 2021, 'MP50-05 INTERIM RESULTS FROM THE DETECT TRIAL: A PROSPECTIVE CLINICAL TRIAL EVALUATING ^99M TC-LABELLED PSMA RADIOGUIDED SURGERY TO AID THE INTRAOPERATIVE DETECTION OF LYMPH NODE METASTASES DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000002076.05

Journal articles | 2021

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; Van Leeuwen PJ; Van Der Poel HG, 2021, 'Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT', European Urology Open Science, 33, pp. S194 - S197, http://dx.doi.org/10.1016/s2666-1683(21)03074-3

Journal articles | 2021

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID; Dhiantravan N; Ford K; Langford A; Lawrence N; McDonald W; Rana N; Subramaniam S; Yip S, 2021, '[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', The Lancet, 397, pp. 797 - 804, http://dx.doi.org/10.1016/S0140-6736(21)00237-3

Journal articles | 2021

Hofman MS; Sandhu S; Francis RJ; Davis ID; Emmett L, 2021, 'Targeted radioactive therapy for prostate cancer – Authors' reply', The Lancet, 398, pp. 488, http://dx.doi.org/10.1016/S0140-6736(21)01060-6

Journal articles | 2021

Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA, 2021, 'Prostate-specific membrane antigen PET in prostate cancer', Radiology, 299, pp. 248 - 260, http://dx.doi.org/10.1148/RADIOL.2021202771

Journal articles | 2021

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2021, 'Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of ¹⁸F-DCFPyL PET/CT Restaging', Advances in Radiation Oncology, 6, http://dx.doi.org/10.1016/j.adro.2020.08.010

Journal articles | 2021

Long GV; Atkinson V; Lo S; Guminski AD; Sandhu SK; Brown MP; Gonzalez M; Scolyer RA; Emmett L; McArthur GA; Menzies AM, 2021, 'Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).', Journal of Clinical Oncology, 39, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9508

Journal articles | 2021

Luiting HB; Remmers S; Meijer D; Vis AN; Donswijk M; Oprea-Lager DE; Emmett L; Rauscher I; Van der Poel HG; Roobol MJ; van Leeuwen PJ, 2021, 'External Validation of Two Nomograms Developed for ⁶⁸Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer ¹⁸F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?', European Urology Open Science, 28, pp. 47 - 51, http://dx.doi.org/10.1016/j.euros.2021.04.002

Journal articles | 2021

McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ, 2021, 'Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review', Advances in Urology, 2021, pp. 1 - 9, http://dx.doi.org/10.1155/2021/1544208

Journal articles | 2021

Mei R; Bracarda S; Emmett L; Farolfi A; Lambertini A; Fanti S; Castellucci P, 2021, 'Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [⁶⁸Ga]-Ga-PSMA-11 PET/CT', Clinical and Translational Imaging, 9, pp. 215 - 220, http://dx.doi.org/10.1007/s40336-021-00421-4

Journal articles | 2021

Meijer D; Van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van De Ven PM; Van Der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External validation and addition of PSMA-PET to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An international multicenter study', European Urology Open Science, 33, pp. S191 - S193, http://dx.doi.org/10.1016/s2666-1683(21)03073-1

Journal articles | 2021

Meijer D; van Leeuwen P; Roberts M; Siriwardana A; Morton A; Yaxley J; Samaratunga H; Emmett L; van de Ven P; van der Poel H; Donswijk M; Boellaard T; Schoots I; Oprea-Lager D; Coughlin G; Vis A, 2021, 'MP11-13 EXTERNAL VALIDATION AND ADDITION OF PSMA-PET TO THE MOST FREQUENTLY USED NOMOGRAMS FOR THE PREDICTION OF PELVIC LYMPH-NODE METASTASES: AN INTERNATIONAL MULTICENTER STUDY', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000001984.13

Journal articles | 2021

Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study', European Urology, 80, pp. 234 - 242, http://dx.doi.org/10.1016/j.eururo.2021.05.006

Journal articles | 2021

R Di Ciaccio P; Emmett L; Hamad N, 2021, 'Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer', Internal Medicine Journal, 51, pp. 1722 - 1726, http://dx.doi.org/10.1111/imj.15515

Journal articles | 2021

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, '⁶⁸Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 477 - 482, http://dx.doi.org/10.1007/s00259-020-04944-2

Journal articles | 2021

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, 'Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 655 - 656, http://dx.doi.org/10.1007/s00259-020-04983-9

Journal articles | 2021

Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL, 2021, 'Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma', Annals of Surgical Oncology, 28, pp. 4561 - 4569, http://dx.doi.org/10.1245/s10434-020-09270-3

Journal articles | 2021

Zamboglou C; Schmidt-Hegemann NS; Emmett L; Strouthos I; Ferentinos K; Serani F; Farolfi A; Fanti S; Federica M; Lanzafame H; Kirste S; Ruf J; Vrachimis A; Ceci F; Grosu AL; Henkenberens C, 2021, 'Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis', European Urology Open Science, 33, pp. S261 - S262, http://dx.doi.org/10.1016/s2666-1683(21)03122-0

Journal articles | 2020

Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L, 2020, 'Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer', BJU International, 125, pp. 515 - 524, http://dx.doi.org/10.1111/bju.14999

Journal articles | 2020

Emmett L; Hofman MS, 2020, 'Editorial Comment', Journal of Urology, 203, pp. 99, http://dx.doi.org/10.1097/01.JU.0000605568.03568.2c

Journal articles | 2020

Emmett L; Hruby G, 2020, 'Clinical impact of PET imaging in prostate cancer management', Current Opinion in Urology, 30, pp. 649 - 653, http://dx.doi.org/10.1097/MOU.0000000000000795

Journal articles | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Journal articles | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Journal articles | 2020

Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P, 2020, '3-year freedom from progression after ⁶⁸Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial', Journal of Nuclear Medicine, 61, pp. 866 - 872, http://dx.doi.org/10.2967/jnumed.119.235028

Journal articles | 2020

Emmett L, 2020, 'Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer', Seminars in Oncology Nursing, 36, http://dx.doi.org/10.1016/j.soncn.2020.151052

Journal articles | 2020

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5500

Journal articles | 2020

Holtkamp LHJ; Chakera AH; Fung S; Stretch JR; Saw RPM; Lee K; Ch'Ng S; Gonzalez M; Thompson JF; Emmett L; Nieweg OE, 2020, 'Staging ¹⁸F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases', Melanoma Research, 30, pp. 358 - 363, http://dx.doi.org/10.1097/CMR.0000000000000666

Journal articles | 2020

Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ, 2020, 'Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection', BJU International, 125, pp. 876 - 883, http://dx.doi.org/10.1111/bju.15052

Journal articles | 2020

Lee J; Emmett L; Tang R; Ho B; Earls P; Matthews T; Gallagher R, 2020, 'Prospective evaluation of the impact of human papilloma virus status and small node size on the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for primary head and neck squamous cell carcinoma', ANZ Journal of Surgery, 90, pp. 1396 - 1401, http://dx.doi.org/10.1111/ans.16093

Journal articles | 2020

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2020, 'A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy', International Journal of Radiation Oncology Biology Physics, 106, pp. 546 - 555, http://dx.doi.org/10.1016/j.ijrobp.2019.11.001

Journal articles | 2020

Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ, 2020, 'Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature', BJU International, 125, pp. 206 - 214, http://dx.doi.org/10.1111/bju.14944

Journal articles | 2019

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Journal articles | 2019

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Journal articles | 2019

Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM, 2019, 'Prospective, multisite, international comparison of ¹⁸F-fluoromethylcholine PET/CT, multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: Clinical performance and patient outcomes', Journal of Nuclear Medicine, 60, pp. 794 - 800, http://dx.doi.org/10.2967/jnumed.118.220103

Journal articles | 2019

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Journal articles | 2019

Fendler WP; Calais J; Eiber M; Flavell RR; Mishoe A; Feng FY; Nguyen HG; Reiter RE; Rettig MB; Okamoto S; Emmett L; Zacho HD; Ilhan H; Wetter A; Rischpler C; Schoder H; Burger IA; Gartmann J; Smith R; Small EJ; Slavik R; Carroll PR; Herrmann K; Czernin J; Hope TA, 2019, 'Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial', JAMA Oncology, 5, pp. 856 - 863, http://dx.doi.org/10.1001/jamaoncol.2019.0096

Journal articles | 2019

Hofman MS; Emmett L; Violet J; Y. Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; Davis ID, 2019, 'TheraP: a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)', BJU International, 124, pp. 5 - 13, http://dx.doi.org/10.1111/bju.14876

Journal articles | 2019

Hofman MS; Emmett L, 2019, 'Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?', European Urology, 76, pp. 479 - 481, http://dx.doi.org/10.1016/j.eururo.2019.07.030

Journal articles | 2019

Lieng H; Kneebone A; Hayden AJ; Christie DRH; Davis BJ; Eade TN; Emmett L; Holt T; Hruby G; Pryor D; Sidhom M; Skala M; Yaxley J; Shakespeare TP, 2019, 'Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology, 140, pp. 68 - 75, http://dx.doi.org/10.1016/j.radonc.2019.05.016

Journal articles | 2019

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman G, 2019, '2 Drive: Defining Radiorecurrent Intraprostatic Target Volumes', Radiotherapy and Oncology, 139, pp. S4 - S4, http://dx.doi.org/10.1016/s0167-8140(19)33259-1

Journal articles | 2019

Long GV; Atkinson VG; Lo S; Sandhu SK; Brown M; Gonzalez M; Guminski A; Scolyer RA; Emmett L; Menzies AM; McArthur GA, 2019, 'Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)', Annals of Oncology, 30, pp. v534 - v534, http://dx.doi.org/10.1093/annonc/mdz255.001

Journal articles | 2019

Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM, 2019, 'Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial', The Lancet Oncology, 20, pp. 961 - 971, http://dx.doi.org/10.1016/S1470-2045(19)30331-6

Journal articles | 2019

Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L, 2019, 'The contribution of multiparametric pelvic and whole-body MRI to interpretation of ¹⁸F-fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy', Journal of Nuclear Medicine, 60, pp. 1253 - 1258, http://dx.doi.org/10.2967/jnumed.118.225185

Journal articles | 2019

Nandurkar R; Van Leeuwen P; Stricker P; Woo H; Kooner R; Yuen C; O'Neill G; Ende D; Cusick T; Ho B; Hickey A; Emmett L, 2019, '68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery', British Journal of Radiology, 92, pp. 20180667, http://dx.doi.org/10.1259/bjr.20180667

Journal articles | 2019

Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L, 2019, 'Diagnostic accuracy of ⁶⁸Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ⁶⁸Ga-PSMA PET to mpMRI', BJU International, 124, pp. 42 - 49, http://dx.doi.org/10.1111/bju.14794

Journal articles | 2019

Yin C; Ho B; Chan L; Emmett L, 2019, 'Asymptomatic Prostate Cancer Brain Metastases on 68Ga-PSMA PET/CT', Clinical Nuclear Medicine, 44, pp. E382 - E384, http://dx.doi.org/10.1097/RLU.0000000000002548

Journal articles | 2019

van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L, 2019, 'Gallium-68-prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer', BJU International, 124, pp. 62 - 68, http://dx.doi.org/10.1111/bju.14506

Journal articles | 2019

van Leeuwen PJ; Emmett L; Donswijk ML; Stricker PD; Pos FJ; Wit E; van der Poel HG, 2019, 'Early outcomes after [⁶⁸Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy', Tijdschrift voor Urologie, 9, pp. 2 - 8, http://dx.doi.org/10.1007/s13629-018-00215-w

Journal articles | 2018

Byrne K; Eade T; Kneebone A; Guo L; Hsiao E; Schembri G; Kwong C; Hunter J; Emmett L; Hruby G, 2018, 'Delineating sites of failure following post-prostatectomy radiation treatment using ⁶⁸Ga-PSMA-PET', Radiotherapy and Oncology, 126, pp. 244 - 248, http://dx.doi.org/10.1016/j.radonc.2017.10.022

Journal articles | 2018

Deenick EK; Morey A; Danta M; Emmett L; Fay K; Gracie G; Ma CS; Macintosh R; Smith SABC; Sasson SC; Sewell WA; Cowley M; Tangye SG; Kelleher AD; Phan TG, 2018, 'Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency', Journal of Clinical Immunology, 38, pp. 159 - 162, http://dx.doi.org/10.1007/s10875-018-0477-z

Journal articles | 2018

Emmett L; Metzer U; Bauman G; Pouliot F; Hicks R; Chua S; Davis I; Punwani S; Weikhardt A; Scott A, 2018, 'Prospective, multinational comparison of magnetic resonance imaging (mp-MRI and WB–MRI) F-18 fluorocholine (FCH) and Ga-68 PSMA in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy', European Urology Supplements, 17, pp. e583 - e583, http://dx.doi.org/10.1016/s1569-9056(18)31246-6

Journal articles | 2018

Emmett L; Nandurkar R; Van Leeuwen P; Woo H; Kooner R; Ende D; O’Neill G; Yuen C; Ho B; Nguyen Q; Hickey A; Stricker P, 2018, 'Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery', European Urology Supplements, 17, pp. e1903 - e1903, http://dx.doi.org/10.1016/s1569-9056(18)32310-8

Journal articles | 2018

Hope TA; Afshar-Oromieh A; Eiber M; Emmett L; Fendler WP; Lawhn-Heath C; Rowe SP, 2018, 'Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications', American Journal of Roentgenology, 211, pp. 286 - 294, http://dx.doi.org/10.2214/AJR.18.19957

Journal articles | 2018

Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A, 2018, '⁶⁸Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer', Asia-Pacific Journal of Clinical Oncology, 14, pp. 343 - 346, http://dx.doi.org/10.1111/ajco.12872

Journal articles | 2018

Lieng H; Hayden AJ; Christie DRH; Davis BJ; Eade TN; Emmett L; Holt T; Hruby G; Pryor D; Shakespeare TP; Sidhom M; Skala M; Wiltshire K; Yaxley J; Kneebone A, 2018, 'Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology, 129, pp. 377 - 386, http://dx.doi.org/10.1016/j.radonc.2018.06.027

Journal articles | 2018

Pouliot F; Bauman G; Chua S; Davis I; Hicks R; Metser U; Punwani S; Scott A; Weickhardt A; Emmett L, 2018, 'PD37-02 A PROSPECTIVE MULTICENTER STUDY COMPARING MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MP-MRI), F-18 FLUORO-METHYL-CHOLINE (FCH) AND GA-68 HBED-CC- (PSMA) POSITRON EMISSION TOMOGRAPHY IN PATIENTS BEING CONSIDERED FOR SALVAGE RADIATION THERAPY FOR BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY', Journal of Urology, 199, http://dx.doi.org/10.1016/j.juro.2018.02.1737

Journal articles | 2018

Roach PJ; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen QA; Thompson BD; Cusick T; McCarthy M; Tang C; Ho B; Stricker PD; Scott AM, 2018, 'The impact of ⁶⁸ Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study', Journal of Nuclear Medicine, 59, pp. 82 - 88, http://dx.doi.org/10.2967/jnumed.117.197160

Journal articles | 2018

Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM, 2018, 'FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 29, pp. 2115 - 2120, http://dx.doi.org/10.1093/annonc/mdy330

Journal articles | 2018

2018, '2018 CUA Abstracts.', Can Urol Assoc J, 12, pp. S51 - S136, https://www.ncbi.nlm.nih.gov/pubmed/29877793

Journal articles | 2017

Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH, 2017, 'Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis', Prostate Cancer and Prostatic Diseases, 20, pp. 352 - 360, http://dx.doi.org/10.1038/pcan.2017.23

Journal articles | 2017

Emmett L; Van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P, 2017, 'Treatment outcomes from ⁶⁸Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET', Journal of Nuclear Medicine, 58, pp. 1972 - 1976, http://dx.doi.org/10.2967/jnumed.117.196683

Journal articles | 2017

Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J, 2017, 'Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy', Journal of Medical Radiation Sciences, 64, pp. 52 - 60, http://dx.doi.org/10.1002/jmrs.227

Journal articles | 2017

Fanti S; Minozzi S; Morigi JJ; Giesel F; Ceci F; Uprimny C; Hofman MS; Eiber M; Schwarzenbock S; Castellucci P; Bellisario C; Chauvie S; Bergesio F; Emmett L; Haberkorn U; Virgolini I; Schwaiger M; Hicks RJ; Krause BJ; Chiti A, 2017, 'Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions', European Journal of Nuclear Medicine and Molecular Imaging, 44, pp. 1622 - 1635, http://dx.doi.org/10.1007/s00259-017-3725-1

Journal articles | 2017

Fendler WP; Calais J; Allen-Auerbach M; Bluemel C; Eberhardt N; Emmett L; Gupta P; Hartenbach M; Hope TA; Okamoto S; Helmut Pfob C; Pöppel TD; Rischpler C; Schwarzenböck S; Stebner V; Unterrainer M; Zacho HD; Maurer T; Gratzke C; Crispin A; Czernin J; Herrmann K; Eiber M, 2017, '⁶⁸Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: An international multicenter prospective study', Journal of Nuclear Medicine, 58, pp. 1617 - 1623, http://dx.doi.org/10.2967/jnumed.117.190827

Journal articles | 2017

Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L, 2017, 'Frusemide aids diagnostic interpretation of ⁶⁸Ga-PSMA positron emission tomography/CT in men with prostate cancer', Journal of Medical Imaging and Radiation Oncology, 61, pp. 739 - 744, http://dx.doi.org/10.1111/1754-9485.12625

Journal articles | 2017

Gonzalez M; Menzies AM; Saw R; Thompson JF; Spillane AJ; Howle J; Nieweg O; Shannon K; Ch'Ng S; Stretch JF; Carlino MS; Guminski A; Emmett L; Rizos H; Scolyer RA; Long GV, 2017, 'A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)', Annals of Oncology, 28, pp. v445 - v445, http://dx.doi.org/10.1093/annonc/mdx377.041

Journal articles | 2017

Holtkamp LHJ; Read RL; Emmett L; Thompson JF; Nieweg OE, 2017, 'Futility of imaging to stage melanoma patients with a positive sentinel lymph node', Melanoma Research, 27, pp. 457 - 462, http://dx.doi.org/10.1097/CMR.0000000000000362

Journal articles | 2017

Hruby G; Eade T; Kneebone A; Emmett L; Guo L; Ho B; Hsiao E; Schembri G; Hunter J; Kwong C, 2017, 'Delineating biochemical failure with ⁶⁸Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer', Radiotherapy and Oncology, 122, pp. 99 - 102, http://dx.doi.org/10.1016/j.radonc.2016.11.023

Journal articles | 2017

Long GV; Atkinson V; Menzies AM; Lo S; Guminski AD; Brown MP; Gonzalez MM; Diamante K; Sandhu SK; Scolyer RA; Emmett L; McArthur GA, 2017, 'A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).', Journal of Clinical Oncology, 35, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9508

Journal articles | 2017

Menzies AM; Gonzalez M; Guminski A; Nieweg O; Shannon K; Thompson JF; Kefford R; Ch'Ng S; Stretch J; Spillane AJ; Lee J; Lee H; Kapoor R; Emmett L; Rizos H; Saw RP; Scolyer RA; Long GV, 2017, 'Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma', Annals of Oncology, 28, pp. v432 - v432, http://dx.doi.org/10.1093/annonc/mdx377.007

Journal articles | 2017

Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P, 2017, 'Initial multicentre experience of ⁶⁸gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited', BJU International, 120, pp. 673 - 681, http://dx.doi.org/10.1111/bju.13919

Journal articles | 2017

Stodell M; Thompson JF; Emmett L; Uren RF; Kapoor R; Saw RPM, 2017, 'Melanoma patient imaging in the era of effective systemic therapies', European Journal of Surgical Oncology, 43, pp. 1517 - 1527, http://dx.doi.org/10.1016/j.ejso.2017.05.014

Journal articles | 2017

van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD, 2017, 'Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer', BJU International, 119, pp. 209 - 215, http://dx.doi.org/10.1111/bju.13540

Journal articles | 2016

Bhatia KD; Ambati C; Dhaliwal R; Paschkewitz R; Hsu E; Ho B; Young A; Emmett L, 2016, 'SPECT-CT/VQ versus CTPA for diagnosing pulmonary embolus and other lung pathology: Pre-existing lung disease should not be a contraindication', Journal of Medical Imaging and Radiation Oncology, 60, pp. 492 - 497, http://dx.doi.org/10.1111/1754-9485.12471

Journal articles | 2016

Kanthan GL; Izard MA; Emmett L; Hsiao E; Schembri GP, 2016, 'Schwannoma showing avid uptake on 68Ga-PSMA-HBED-CC PET/CT', Clinical Nuclear Medicine, 41, pp. 703 - 704, http://dx.doi.org/10.1097/RLU.0000000000001281

Journal articles | 2016

Lee P; Bova R; Schofield L; Bryant W; Dieckmann W; Slattery A; Govendir MA; Emmett L; Greenfield JR, 2016, 'Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans', Cell Metabolism, 23, pp. 602 - 609, http://dx.doi.org/10.1016/j.cmet.2016.02.007

Journal articles | 2016

Long GV; Atkinson V; Menzies AM; Guminski AD; Sandhu SK; Brown MP; Liaw T; Gonzalez M; Davison J; Paton EJ; Scolyer RA; Emmett L; McArthur GA, 2016, 'A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).', Journal of Clinical Oncology, 34, pp. TPS9591 - TPS9591, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.tps9591

Journal articles | 2016

Tang R; Wang JTY; Wang L; Le K; Huang Y; Hickey AJ; Emmett L, 2016, 'Impact of patient preparation on the diagnostic performance of ¹⁸F-FDG PET in cardiac sarcoidosis a systematic review and meta-analysis', Clinical Nuclear Medicine, 41, pp. e327 - e339, http://dx.doi.org/10.1097/RLU.0000000000001063

Journal articles | 2016

Van Leeuwen P; Emmett L; Ho B; Delprado W; Stricker P, 2016, '559 Prospective evaluation of 68Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer', European Urology Supplements, 15, pp. e559 - e559, http://dx.doi.org/10.1016/s1569-9056(16)60561-4

Journal articles | 2016

Van Leeuwen PJ; Emmett L; Hruby G; Kneebone A; Stricker P, 2016, '548 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment', European Urology Supplements, 15, pp. e548 - e548, http://dx.doi.org/10.1016/s1569-9056(16)60550-x

Journal articles | 2015

Emmett L, 2015, '68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.', BJU International, 117, pp. 732 - 739, http://dx.doi.org/10.1111/bju.13397

Journal articles | 2015

Emmett L, 2015, 'Prognostic and diagnostic implications of nonperfusion data on SPECT myocardial perfusion imaging', Current Cardiovascular Imaging Reports, 8, pp. 1 - 9, http://dx.doi.org/10.1007/s12410-014-9307-8

Journal articles | 2015

Morigi JJ; Stricker PD; Van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L, 2015, 'Prospective Comparison of ¹⁸F-Fluoromethylcholine Versus ⁶⁸Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy', Journal of Nuclear Medicine, 56, pp. 1185 - 1190, http://dx.doi.org/10.2967/jnumed.115.160382

Journal articles | 2015

Wang LW; Omari A; Emmett L; Jansz PC; Huilgol R; Rainer S; Subbiah RN, 2015, 'Granulomatous sarcoid aortitis: A serious complication of a well-known multisystem disease', The Lancet, 385, pp. 2014, http://dx.doi.org/10.1016/S0140-6736(15)60649-3

Journal articles | 2014

Naehrig D; Uren RF; Emmett L; Ioannou K; Hong A; Wratten C; Thompson JF; Hruby G, 2014, 'Sentinel lymph node mapping for defining site and extent of elective radiotherapy management of regional nodes in Merkel cell carcinoma: A pilot case series', Journal of Medical Imaging and Radiation Oncology, 58, pp. 353 - 359, http://dx.doi.org/10.1111/1754-9485.12180

Journal articles | 2014

Sasson S; Smith S; Sewell WA; Morey A; Danta M; Emmett L; Kelleher AD; Fay K; Phan T, 2014, 'MONOCLONAL B-CELL POPULATION OF INDETERMINANT MALIGNANT POTENTIAL IN THE SETTING OF ATYPICAL CVID ASSOCIATED WITH LYMPHADENOPATHY AND SPLENOMEGALY', INTERNAL MEDICINE JOURNAL, 44, pp. 33 - 33, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342722800109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2013

Brungs D; Sze V; Emmett L; Epstein RJ, 2013, 'Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy.', World J Oncol, 4, pp. 122 - 125, http://dx.doi.org/10.4021/wjon639w

Journal articles | 2012

Emmett L; Ho B, 2012, 'Imaging for melanoma and non-melanoma skin cancers', Cancer Forum, 36

Journal articles | 2012

Emmett L; Ng A; Ha L; Russo R; Mansberg R; Zhao W; Chow SV; Kritharides L, 2012, 'Comparative assessment of rest and post-stress left ventricular volumes and left ventricular ejection fraction on gated myocardial perfusion imaging (MPI) and echocardiography in patients with transient ischaemic dilation on adenosine MPI: Myocardial stunning or subendocardial hypoperfusion?', Journal of Nuclear Cardiology, 19, pp. 735 - 742, http://dx.doi.org/10.1007/s12350-012-9571-4

Journal articles | 2012

Emmett L, 2012, 'Disparate physical measurements of the left ventricle on concurrent Adenosine Myocardial Perfusion Imaging (MPI) and Echocardiography in patients with Transient ischaemic dilation and stunning of the left ventricle on MPI.', Journal of Nuclear Cardiology

Journal articles | 2011

Girgis CM; Wong T; Ngu MC; Emmett L; Archer KA; Chen RC; Seibel MJ, 2011, 'Hypophosphataemic osteomalacia in patients on adefovir dipivoxil', Journal of Clinical Gastroenterology, 45, pp. 468 - 473, http://dx.doi.org/10.1097/MCG.0b013e3181e12ed3

Journal articles | 2010

Chung SCS; Peters MJ; Chen S; Emmett L; Ing AJ, 2010, 'Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: A pilot study', Respirology, 15, pp. 1079 - 1083, http://dx.doi.org/10.1111/j.1440-1843.2010.01815.x

Journal articles | 2010

Russo RR; Emmett L; Mansberg R; Fung KC, 2010, 'Severe ischaemia on SPECT myocardial perfusion imaging secondary to microvascular dysfunction and apical hypertrophic cardiomyopathy', Clinical Nuclear Medicine, 35, pp. 937 - 940, http://dx.doi.org/10.1097/RLU.0b013e3181f9de3c

Journal articles | 2010

Russo RR; Ha L; Emmett L; Magee M; Mansberg R, 2010, 'Progressive visual loss due to obstruction of an optic nerve sheath fenestration demonstrated on SPECT/CT radionuclide cisternography', Clinical Nuclear Medicine, 35, pp. 208 - 210, http://dx.doi.org/10.1097/RLU.0b013e3181cc647a

Journal articles | 2010

Seccombe LM; Chung SCS; Jenkins CR; Frater CJ; Mackey DWJ; Pearson MA; Emmett L; Peters MJ, 2010, 'Lung perfusion and chest wall configuration is altered by glossopharyngeal breathing', European Respiratory Journal, 36, pp. 151 - 156, http://dx.doi.org/10.1183/09031936.00163209

Journal articles | 2010

Wong T; Girgis CM; Ngu MC; Chen RCY; Emmett L; Archer KA; Seibel MJ, 2010, 'Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B', Journal of Clinical Endocrinology and Metabolism, 95, pp. 479 - 480, http://dx.doi.org/10.1210/jc.2009-2051

Journal articles | 2009

Emmett L; Ng A; Russo R; Zhang W; Yong A; Freedman SB; Kritharides L, 2009, 'Transient Ischaemic Dilation on Tc99m Adenosine Myocardial Perfusion Imaging is not due to Left Ventricular Cavity Dilation or Stunning: Comparison of Echocardiography and Myocardial Perfusion Imaging', Heart, Lung and Circulation, 18, pp. S44 - S44, http://dx.doi.org/10.1016/j.hlc.2009.05.096

Journal articles | 2009

Ha L; Mansberg R; Van Der Wall H; Emmett L; Magee M, 2009, 'Increased in-111 octreotide uptake due to paget disease and a low midline pelvic kidney', Clinical Nuclear Medicine, 34, pp. 84 - 86, http://dx.doi.org/10.1097/RLU.0b013e318192c4fc

Journal articles | 2009

Mansberg R; Nicholls M; Chan C; Emmett L; Van Der Wall H, 2009, 'Tuberculous epididymo-orchitis presenting as pyrexia of unknown origin during acute myeloid leukaemia consolidation therapy', Internal Medicine Journal, 39, pp. 137 - 138, http://dx.doi.org/10.1111/j.1445-5994.2008.01866.x

Journal articles | 2009

Russo RR; Lee A; Mansberg R; Emmett L, 2009, 'Hypertrophic pulmonary osteoarthropathy demonstrated on SPECT/CT', Clinical Nuclear Medicine, 34, pp. 628 - 631, http://dx.doi.org/10.1097/RLU.0b013e3181b06c9c

Journal articles | 2008

Emmett L; Van Gaal WJ; Magee M; Bass S; Ali O; Freedman SB; Van der Wall H; Kritharides L, 2008, 'Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging', Journal of Nuclear Cardiology, 15, pp. 638 - 643, http://dx.doi.org/10.1016/j.nuclcard.2008.06.005

Journal articles | 2008

Lee A; Emmett L; Van Der Wall H; Kannangara S; Mansberg R; Fogelman I, 2008, 'SPECT/CT of femeroacetabular impingement', Clinical Nuclear Medicine, 33, pp. 757 - 762, http://dx.doi.org/10.1097/RLU.0b013e318187ef6b

Journal articles | 2007

Chung T; Connor D; Joseph J; Emmett L; Mansberg R; Ma D; Kritharides L, 2007, 'Shedding of P-selectin from Activated Platelets Correlates with the Severity of Right Ventricular Dysfunction During Acute Pulmonary Embolism', Heart, Lung and Circulation, 16, pp. S61 - S61, http://dx.doi.org/10.1016/j.hlc.2007.06.157

Journal articles | 2007

Chung T; Emmett L; Mansberg R; Peters M; Kritharides L, 2007, 'Natural History of Right Ventricular Dysfunction After Acute Pulmonary Embolism', Journal of the American Society of Echocardiography, 20, pp. 885 - 894, http://dx.doi.org/10.1016/j.echo.2006.12.005

Journal articles | 2007

Chung TS; Connor DE; Joseph JE; Emmett L; Mansberg R; Peters MW; Ma DD; Kritharides L, 2007, 'Platelet activation in acute pulmonary embolism', Journal of Thrombosis and Haemostasis, 5, pp. 918 - 924, http://dx.doi.org/10.1111/j.1538-7836.2007.02461.x

Journal articles | 2006

Chung T; Emmett L; Khoury V; Lau GT; Elsik M; Foo F; Allman KC; Kritharides L, 2006, 'Atrial and ventricular echocardiographic correlates of the extent of pulmonary embolism in the elderly', Journal of the American Society of Echocardiography, 19, pp. 347 - 353, http://dx.doi.org/10.1016/j.echo.2005.09.012

Journal articles | 2006

Vu DH, 2006, 'Bone scintigraphy predicts outcome of steroid injection for plantar fasciitis', Journal of Nuclear Medicine, 47, pp. 1577 - 1580

Journal articles | 2005

Emmett L; Magee M; Freedman SB; Van Der Wall H; Bush V; Trieu J; Van Gaal W; Allman KC; Kritharides L, 2005, 'The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation of the left ventricle on myocardial perfusion SPECT images', Journal of Nuclear Medicine, 46, pp. 1596 - 1601

Journal articles | 2005

Emmett L, 2005, 'Electrocardiographic prediction of the severity of posterior wall perfusion defects on rest technetium-99m Sestamibi myocardial perfusion imaging.', Journal of Electrocardiology, 38, pp. 195 - 203, http://dx.doi.org/10.1016/j.jelectrocard.2005.03.007

Journal articles | 2004

Trieu J; Emmett L; Perera C; Thanakrishnan K; Van Der Wall H, 2004, 'Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy', Clinical Nuclear Medicine, 29, pp. 803 - 804, http://dx.doi.org/10.1097/00003072-200412000-00008

Journal articles | 2003

Emmett L; Husain M; Barolet A; Lee D; Iwanochko MR, 2003, 'Attenuation correction of ECG-gated TC-99 m sestamibi myocardial perfusion imaging impairs the detection of triple vessel disease on coronary angiography', Heart, Lung and Circulation, 12, pp. A33 - A33, http://dx.doi.org/10.1046/j.1443-9506.2003.01521.x

Journal articles | 2002

Emmett L, 2002, 'Reversible regional wall motion abnormalities on exercise technetium-99m-gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses.', J Am Coll Cardiol, 39, pp. 991 - 998, http://dx.doi.org/10.1016/S0735-1097(02)01707-2

Journal articles | 2002

Frater C; Emmett L; Van Gaal W; Sungaran J; Devakumar D; Van Der Wall H, 2002, 'A Critical Appraisal of Pinhole Scintigraphy of the Ankle and Foot', Clinical Nuclear Medicine, 27, pp. 707 - 710, http://dx.doi.org/10.1097/00003072-200210000-00005

Journal articles | 2001

Chicco P; Magnussen JS; Mackey DW; Bush V; Emmett L; Storey G; Bautovich G; Van Der Wall H, 2001, 'SPET of a computerised model of diffuse lung disease', European Journal of Nuclear Medicine, 28, pp. 150 - 154, http://dx.doi.org/10.1007/s002590000425

Journal articles | 2001

EMMETT L; IWANOCHKO R; BAROLET A; HUSAIN M, 2001, '2.4 Correlation of rest-stress gated SPECT determined regional wall motion abnormalities with coronary angiographic stenoses', Journal of Nuclear Cardiology, 8, pp. S16 - S16, http://dx.doi.org/10.1016/s1071-3581(01)80492-x

Journal articles | 2000

Breit R; Van Der Wall H; Emmett L; Storey G; Allman K, 2000, 'Sunburst periosteal reaction in a bony metastasis', Clinical Nuclear Medicine, 25, pp. 392 - 393, http://dx.doi.org/10.1097/00003072-200005000-00025

Journal articles | 2000

Emmett L; Allman KC, 2000, 'Eikenella corrodens vertebral osteomyelitis', Clinical Nuclear Medicine, 25, pp. 1059 - 1060, http://dx.doi.org/10.1097/00003072-200012000-00032

Journal articles | 2000

Emmett L; Storey G; Marel E; Van Der Wall H, 2000, 'Sequestered collection in association with infected arthroplasty', Clinical Nuclear Medicine, 25, pp. 288 - 289, http://dx.doi.org/10.1097/00003072-200004000-00011

Journal articles | 2000

Magee M; Kannangara S; Dennien B; Lonergan R; Emmett L; Van Der Wall H, 2000, 'Paraspinal abscess complicating facet joint injection', Clinical Nuclear Medicine, 25, pp. 71 - 73, http://dx.doi.org/10.1097/00003072-200001000-00024

Journal articles | 1999

Emmett LM; Patel NC; Thanakrishnan K; Van Der Wall H; Magee M; Allman KC, 1999, 'Extensive rhabdomyolysis after streptokinase therapy for acute myocardial infarction demonstrated by Tc-99m PYP scintigraphy', Clinical Nuclear Medicine, 24, pp. 991 - 992, http://dx.doi.org/10.1097/00003072-199912000-00024

Journal articles | 1999

Tejani A; Stablein DM; Donaldson L; Harmon WE; Alexander SR; Kohaut E; Emmett L; Fine RN, 1999, 'Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience.', Clin Transpl, pp. 95 - 110, https://www.ncbi.nlm.nih.gov/pubmed/11038628

Journal articles | 1999

Van der Wall H; Storey G; Emmett L; Magee M, 1999, 'Pain in the anterior pelvis and postoperative prostatectomy findings', Clinical Nuclear Medicine, 24, pp. 523 - 524, http://dx.doi.org/10.1097/00003072-199907000-00013
Conference Abstracts | 2023

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2023, 'PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study', in Journal of Nuclear Medicine, LIPPINCOTT WILLIAMS & WILKINS, Vol. 64, pp. 1024 - 1029, http://dx.doi.org/10.2967/jnumed.122.265242

Conference Abstracts | 2022

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu SK; Joshua AM; Zhang AY; Francis RJ; Scott AM; Azad A; McJannett MM; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.010

Conference Abstracts | 2022

Doan PN; Counter W; Sheehan-Dare G; Papa N; Ho B; Lee J; Liu V; Thompson J; Agrawal S; Roberts M; Algharzo O; Buteau J; Hofman M; Moon D; Murphy D; Stricker P; Emmett L, 2022, 'Diagnostic accuracy, concordance and certainty with 68Ga-PSMA-11 PET/MRI fusion compared to mpMRI and 68Ga-PSMA-11 PET/CT alone for prostate cancer diagnosis: A PRIMARY trial sub-study', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S1103 - S1104, http://dx.doi.org/10.1016/s0302-2838(22)00822-3

Conference Abstracts | 2022

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

Conference Abstracts | 2022

Eslick E; Counter W; Sharma S; Ayers M; Wong K; Nguyen A; Ho S; Pathmanandavel S; Hickey A; Emmett L, 2022, 'PSMA Screening phenotype allows personalisation of radiation safety recommendations.', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 29 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000794958100059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Conference Abstracts | 2022

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5000

Conference Abstracts | 2022

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5043 - 5043, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5043

Conference Abstracts | 2022

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.032

Conference Abstracts | 2022

Kwok M; McGeorge S; Jiang A; Emmett L; Pattison D; Thomas P; Yaxley J; Roberts M, 2022, 'Dual tracer PET using 68-Ga PSMA and 18-F FDG for staging prostate cancer: A systematic review', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 143 - 143, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters | 2022

Meijer D; Vis A; Roberts M; Siriwardana A; Morton A; Yaxley J; Samaratunga H; Emmett L; van de Ven P; Heijmans M; Van der Poel H; Donswijk M; Boellaard T; Schoots I; Oprea-Lager D; Coughlin G; van Leeuwen P, 2022, 'MP51-03 DEVELOPMENT OF A NOVEL NOMOGRAM TO IDENTIFY CANDIDATES FOR EXTENDED PELVIC LYMPH-NODE DISSECTION IN PROSTATE CANCER USING MRI AND PSMA PET', Vol. 207, http://dx.doi.org/10.1097/ju.0000000000002626.03

Conference Abstracts | 2022

Meijer D; Vis AN; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van de Ven PM; Heijmans MW; Van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Van Leeuwen PJ, 2022, 'Development of a novel nomogram to identify candidates for extended pelvic lymph-node dissection in prostate cancer using MRI and PSMA pet', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S981 - S982, http://dx.doi.org/10.1016/s0302-2838(22)00737-0

Conference Abstracts | 2022

Menzies AM; Saw RPM; Lo SN; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee JHJ; Rizos H; Rawson RV; Stretch J; Thompson JF; Emmett L; Kapoor R; Spillane AJ; Scolyer RA; Long GV, 2022, 'Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 9580 - 9580, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9580

Conference Abstracts | 2022

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Conference Abstracts | 2022

Ptasznik G; Moon D; Emmett L; Papa N; Kelly B; Roberts M; Hofman M; Thompson J; Murphy D; Stricker P, 2022, 'Is a biopsy necessary before offering a radical prostatectomy in all men? An analysis of the PI-RADS 4 & 5 lesions from the PRIMARY trial', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 160 - 161, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Conference Abstracts | 2022

Schmidt-Hegemann N-S; Strouthos J; Farolfi A; Trapp C; Peeken J; Vogel MME; Vrachimis A; Belka C; Grosu A-L; Ceci F; Kroeze S; Guckenberger M; Henkenberens C; Emmett L; Zamboglou C; Wiegel T, 2022, 'Influence of PSMA PET-positive local recurrences on biochemical recurrence free survival after salvage radiotherapy in patients with recurrent or persistent prostate cancer-a multicenter retrospective study', in STRAHLENTHERAPIE UND ONKOLOGIE, SPRINGER HEIDELBERG, GERMANY, Stuttgart, Vol. 198, pp. S39 - S39, presented at 28th Congress of Deutsche-Gesellschaft-fur-Radioonkologie-e-V (DERGO), GERMANY, Stuttgart, 26 May 2022 - 28 May 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000791788000073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Conference Abstracts | 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, 'Cu-64-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300985&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2022

Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C, 2022, 'Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy', in International Journal of Radiation Oncology Biology Physics, SPRINGER HEIDELBERG, pp. 1015 - 1024, http://dx.doi.org/10.1016/j.ijrobp.2022.04.048

Conference Abstracts | 2021

Azad A; Dhiantravan N; Emmett L; Joshua AM; Vela I; Pattison DA; Francis RJ; Williams S; Sandhu SK; Davis ID; Neha N; Bressel M; Murphy DG; Hofman MS, 2021, 'UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS180

Conference Abstracts | 2021

Dimitriou F; Lo S; Tan AC; Emmett L; Kapoor R; Carlino M; Long GV; Menzies AM, 2021, 'FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S880 - S880, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1439

Conference Abstracts | 2021

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Conference Papers | 2021

Gondoputro W; Blazevski A; Amin A; Scheltema M; Agrawal S; Cusick T; Van Leeuwen P; Van Leeuwen F; Emmett L; Thompson J; Stricker P, 2021, 'INTERIM RESULTS FROM THE DETECT TRIAL: A PROSPECTIVE CLINICAL TRIAL EVALUATING (TC)-T-99M-LABELLED PSMA RADIOGUIDED SURGERY TO AID THE INTRAOPERATIVE DETECTION OF LYMPH NODE METASTASES DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER', in JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, pp. E887 - E887, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693689000269&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2021

Hofman M; Emmett L; Iravani A; Sandhu S; Joshua A; Pattison D; Goh J; Kirkwood I; Tan TH; Francis R; Ng S; Rutherford N; Gedye C; Scott A; Lee S-T; Weickhardt A; Ramdave S; Kwan E; Azad A; Macdonald W; Redfern A; Zhang A; Stockler M; Martin A; Davis I, 2021, 'Lu-177-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, ELECTR NETWORK, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), ELECTR NETWORK, 12 June 2021 - 15 June 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600793&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.6

Conference Papers | 2021

Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; Van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External Validation and Addition of PSMA-PET to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, ELECTR NETWORK, pp. S61 - S61, presented at Annual Congress of the European-Association-of-Nuclear-Medicine, ELECTR NETWORK, 20 October 2021 - 23 October 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000709355000082&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2021

Niman R; Wilson P; Emmett L; Pathmanandavel S; Nelson A, 2021, 'Improved clinical feasibility of total tumor burden quantification on 68Ga-PSMA-11 PET/CT through deep learning autosegmentation of organs for automatic physiological uptake removal', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600460&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Conference Abstracts | 2021

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Conference Abstracts | 2021

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Amin A; Blazevski A; Thompson J; Van Leeuwen P; Emmett L; Stricker P, 2020, 'Early Cases from the DETECT trial: Radioguided Surgery with Technetium99 m-labelled PSMA to aid Intraoperative Lymph Node Metastases Detection for Patients Undergoing Radical Prostatectomy and ePLND for Prostate Cancer', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Sydney, Vol. 125, pp. 86 - 87, presented at 73rd Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Sydney, 07 March 2020 - 10 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000518206100169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Amin A; Ende J; Stricker P; Emmett L, 2020, 'Pilot trial comparing the performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/CT in the detection of prostate cancer recurrence in men with rising PSA following radical prostatectomy', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, Vol. 27, pp. 112 - 112, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000585265700272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Gondoputro W; Amin A; Blazevski A; Scheltema M; Van Leeuwen P; Van Leeuwen F; Thompson J; Emmett L; Stricker P, 2020, '99m-technetium-labelled PSMA radioguided surgery for the intraoperative detection of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for prostate cancer: preliminary cases from the DETECT trial', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, Vol. 27, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000585265700282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302345&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Roberts M; Kneebone A; Hruby G; Frydenberg M; Namdarian B; Hofman MS; Murphy D; Williams S; Emmett L, 2020, 'De-Intensification of Post-Prostatectomy Radiotherapy: A survey of clinician opinions', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Roberts M; Tariq A; Morton A; Donato P; Kyle S; Pattison D; Thomas P; Geoff C; Esler R; Dunglison N; Gardiner R; Doi S; Emmett L; Yaxley J, 2020, 'Improved prostate cancer detection and prediction of outcomes using 68Ga PSMA PET/CT: towards non-invasive precision medicine.', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 16, pp. 42 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Amin A; Stricker P; Scheltema M; Blazevski A; Chang J; van Leeuwen P; Quoc N; Ho B; Delprado W; Lee J; Cusick T; Spriensma A; Siriwardena A; O'Neill G; Yuen C; Kooner R; Hruby G; Thompson J; Emmett L, 2019, 'Diagnostic Accuracy of 68GA-PSMA PET and MPMRI to Detect Intra-Prostatic Clinically Significant Prostate Cancer Using Whole-Mount Pathology. Impact of the Addition of 68GA-PSMA PET to MPMRI?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Emmett L; Chalasani V; Kneebone A; Hruby G; Joshua AM, 2019, 'Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade.', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, ITALY, Milan, Vol. 133, pp. S445 - S446, presented at 38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), ITALY, Milan, 26 April 2019 - 30 April 2019, http://dx.doi.org/10.1016/S0167-8140(19)31267-8

Conference Abstracts | 2019

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Hofman M; Emmett L; Violet JA; Lawrence NJ; Williams S; Stockler MR; Francis RJ; Iravani A; Zhang AY; Martin AJ; Azad A; Yip S; Langford A; McJannett MM; Davis ID, 2019, 'TheraP: A randomized phase II trial of [Lu-177]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS332

Conference Abstracts | 2019

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman G, 2019, 'DRIVE: DEFINING RADIORECURRENT INTRAPROSTATIC TARGET VOLUMES', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, CANADA, Halifax, Vol. 139, pp. S4 - S4, presented at Annual Scientific Meeting of the Canadian-Association-for-Radiation-Oncology (CARO), CANADA, Halifax, 02 October 2019 - 05 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493893300003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman GS, 2019, 'DRIVE: Defining Radiorecurrent Intraprostatic Target Volumes', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 105, pp. E291 - E291, presented at 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), IL, Chicago, 15 September 2019 - 18 September 2019, http://dx.doi.org/10.1016/j.ijrobp.2019.06.1834

Conference Abstracts | 2019

Long GV; Atkinson VG; Lo S; Sandhu SK; Brown M; Gonzalez M; Guminski A; Scolyer RA; Emmett L; Menzies AM; McArthur GA, 2019, 'Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 534 - 534, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks R; Weickhardt A; Davis I; Pond G; Scott A; Emmett L, 2019, 'The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800591&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Bauman GS; Metser U; Scott A; Pouliot F; Weickhardt A; Davis I; Hicks R; Punwani S; Chua S; Emmett L, 2018, 'A Prospective Study of F-18 Fluoro-methyl-choline (FCH) And Ga-68 HBED-CC- (PSMA) in Men being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, pp. S162 - S162, presented at 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), TX, San Antonio, 21 October 2018 - 24 October 2018, http://dx.doi.org/10.1016/j.ijrobp.2018.07.016

Conference Papers | 2018

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of Lu-177-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088

Conference Papers | 2018

Emmett L; Joshua A; Epstein R; Chalasani V; Kneebone A; Hruby G; O'Neill G; Stricker P; Stricker P; Quoc N; Ho B, 2018, 'Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), PA, Philadelphia, 23 June 2018 - 26 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000467489900093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Emmett L; Metser U; Bauman G; Hicks R; Pouliot F; Davis I; Chua S; Weickhardt A; Punwani S; Ho B; Johnston E; Scott A, 2018, 'A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, PA, Philadelphia, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), PA, Philadelphia, 23 June 2018 - 26 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000467489900457&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2018

Gielchinsky I; Chang J; Emmett L; Scheltema M; Stricker P; Nguyen Q; Delprado W, 2018, 'False positive intraprostatic lesions on 68 Ga Positron emission tomography in an intermediate prostate cancer cohort: description of a benign cystic cellular pattern with intense PSMA activity', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Melbourne, Vol. 121, pp. 74 - 75, presented at 71st Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, AUSTRALIA, Melbourne, 24 February 2018 - 27 February 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425625700159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Gonzalez M; Menzies AM; Saw R; Spillane AJ; Nieweg OE; Shannon KF; Thompson JF; Howle JR; Ch'ng S; Stretch J; Osorio M; Emmett L; Rizos H; Guminski AD; Carlino MS; Scolyer RA; Long GV, 2018, 'Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D plus T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS9604

Conference Abstracts | 2018

Liu W; Chung HT; Chung P; Zukotynski K; Metser U; Rachinsky I; Wolfson R; Archer S; Emmett L; Bauman GS, 2018, 'Advanced Prostate Imaging of Recurrent Cancer after Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, Vol. 102, pp. E126 - E126, presented at 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), TX, San Antonio, 21 October 2018 - 24 October 2018, http://dx.doi.org/10.1016/j.ijrobp.2018.07.337

Conference Papers | 2018

Tan AC; Emmett L; Lo S; Liu V; Guminski AD; Long GV; Menzies AM, 2018, 'Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.9517

Conference Papers | 2017

Calopedos R; Chalasani V; Asher R; Emmett L; Woo H, 2017, 'Lutetium-177 labelled prostate-specific membrane antigen (PSMA) for metastatic castrate-resistant prostate cancer (MCRPC): a systematic review and meta-analysis', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, pp. 110 - 110, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000406683600308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Calopedos R; Chalasani V; Asher R; Emmett L; Woo HH, 2017, 'LUTETIUM-177 LABELLED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND LIGANDS FOR THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC): A SYSTEMATIC REVIEW AND META-ANALYSIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 41 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427541700048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Emmett L; Lee J; Tang R; Ho B, 2017, 'Impact of small node size on clinical interpretation of F18 FDG PET CT for primary head and neck SCC malignancy. Bad things can come in small packages.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CO, Denver, 10 June 2017 - 14 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404949901025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Fennessy N; Emmett L; Lee J, 2017, 'Frusemide aids diagnostic interpretation of Ga-68-PSMA PET CT in men with Prostate cancer.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CO, Denver, 10 June 2017 - 14 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404949905077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Gonzalez M; Menzies AM; Saw R; Thompson JF; Spillane AJ; Howle J; Nieweg O; Shannon K; Ch'Ng S; Stretch JF; Carlino MS; Guminski A; Emmett L; Rizos H; Scolyer RA; Long GV, 2017, 'A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D plus T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Holtkamp LHJ; Chakera A; Fung S; Stretch J; Saw R; Lee K; Gonzalez M; Thompson J; Emmett L; Nieweg OE, 2017, 'Staging F-18-FDG PET/CT Influences the Melanoma Treatment Plan in Patients with (Micro) Satellites or In-Transit Metastases', in ANNALS OF SURGICAL ONCOLOGY, SPRINGER, WA, Seattle, pp. S131 - S131, presented at 70th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO), WA, Seattle, 15 March 2017 - 18 March 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435672100355&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters | 2017

Joshua AM; Stricker P; Epstein RJ; Ho B; Quoc N; Kent R; Willowson KP; Hofman M; Violet JA; Emmett L, 2017, 'Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of Lu-177 DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)', IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.2562

Conference Papers | 2017

Menzies AM; Gonzalez M; Guminski A; Nieweg O; Shannon K; Thompson JF; Kefford R; Ch'Ng S; Stretch J; Spillane AJ; Lee J; Lee H; Kapoor R; Emmett L; Rizos H; Saw RP; Scolyer RA; Long GV, 2017, 'Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage IIIB/C BRAF V600 mutant melanoma', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2017

Roach P; Francis R; Emmett L; McCarthy M; Scott A, 2017, 'Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, Vol. 58, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CO, Denver, 10 June 2017 - 14 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404949903106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2017

Siriwardana A; Thompson J; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes A-M; Coughlin G; Stricker P, 2017, 'Robot-assisted salvage node dissection for oligometastatic nodal disease detected by 68gallium-PSMA PET/CT: a multicentre retrospective series', in BJU INTERNATIONAL, WILEY-BLACKWELL, Canberra, AUSTRALIA, Vol. 119, pp. 78 - 79, presented at 70th Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Canberra, AUSTRALIA, 24 February 2017 - 27 February 2017, http://dx.doi.org/10.1016/j.juro.2017.02.1661

Conference Papers | 2016

Roach P; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen Q; Thompson B; McCarthy M; Tang C; Brenner P; Stricker P; Scott A, 2016, 'Australian multicentre evaluation of clinical management intent utilising Ga68-PSMA PET scans in patients with prostate cancer', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, SPAIN, Barcelona, pp. S165 - S165, presented at Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), SPAIN, Barcelona, 15 October 2016 - 19 October 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000391801600404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Ali SA; Emmett L; Wang J; Van Leeuwen P; Stark D; Morigi J; Stricker P, 2015, 'A comparison of the utility of F18 Choline and Ga68 PSMA PET/CT in identifying distant disease in high risk prostate cancer patients being considered for radical prostatectomy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S380 - S380, presented at 28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), GERMANY, Hamburg, 10 October 2015 - 14 October 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363013202257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Emmett L, 2015, 'PET-PSMA IN PROSTATE CANCER: CHANGING OUR VIEW OF METASTATIC DISEASE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, AUSTRALIA, Sydney, pp. 30 - 30, presented at ANZUP Annual Scientific Meeting on Redefining Personalised Medicine, AUSTRALIA, Sydney, 12 July 2015 - 14 July 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000362808000028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Morigi J; Stricker P; van Leeuwen P; Tang R; Ho B; Nguyen Q; Hickey A; Stark D; Young A; Fanti S; Tarlinton L; Emmett L, 2015, 'Prospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative intent therapy, being considered for targeted therapy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, GERMANY, Hamburg, pp. S35 - S36, presented at 28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), GERMANY, Hamburg, 10 October 2015 - 14 October 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363013201051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Slattery A; Le K; Emmett L; Young A, 2015, 'USING COMPUTER VISION FOR DETERMINING BONE INVOLVEMENT FOR LYMPHOMA PATIENTS WITH PET-CT IMAGES', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 2 - 2, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000353038000005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Zhang LF; Emmett L; Milner B; Belousova N; Clifford L; Havryk A; Stone E, 2015, 'Pilot introduction of the IASLC nodal classification system across EBUS-TBNA, CT and PET in staging of Non Small Cell Lung Cancer', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S681 - S681, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370365103281&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

van Leeuwen P; Stricker P; Morigi JJ; Quoc N; Kneebone A; Emmett L, 2015, 'Prospective comparison of the detection rate of F-18-Fluoromethylcholine and Ga-68-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Cairns, pp. 29 - 29, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Clack M; Emmett L; Szeto E; Chan L; Ho B, 2014, 'ATTENUATION CORRECTION IN MYOCARDIAL PERFUSION IMAGING: A COMPARATIVE STUDY BETWEEN PRONE AND CTAC', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000334282000053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Al Cheikh E; Emmett L; Russo R, 2012, 'A COMPARATIVE EVALUATION OF PLANAR VS SPECT/CT IN THE ASSESSMENT OF SACROILIAC JOINT ACTIVITY', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Droguett-Fuhrer N; Emmett L; Russo R; Al Cheikh E; Sorensen N, 2012, 'QUANTITATIVE ANALYSIS OF BLOOD POOL SPECT IMAGES IN THE EVALUATION OF THE SACROILIAC JOINTS', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Sorensen N; Emmett L; Tow J, 2012, 'DETERMINING APPROPRIATE PROCESSING METHOD FOR SPECT DATA OF LYMPHOSCINTIGRAPHY SCANNING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 6 - 6, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307882100018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2011

Al Cheikh E; Emmett L; Russo R; Mansberg R; Magee M; Yung G, 2011, 'DEVELOPMENT OF AN AGE AND SEX MATCHED NORMAL DATABASE FOR QUANTITATIVE SACROILIAC UPTAKE ON SPECT/CT Tc-99m-MDP BONE IMAGING', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 24 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000292514200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2011

Emmett L; Ng A; Sorensen N; Mansberg R; Kritharides L, 2011, 'Transient Ischaemic Dilation on Tc99m Adenosine Myocardial perfusion Imaging is not due to left ventricular cavity dilation or stunning. Comparison of echocardiography and myocardial perfusion imaging', in EUROPEAN HEART JOURNAL SUPPLEMENTS, OXFORD UNIV PRESS, NETHERLANDS, Amsterdam, pp. A59 - A59, presented at 10th International Conference of Non-Invasive Cardiovascular Imaging, NETHERLANDS, Amsterdam, 15 May 2011 - 18 May 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000291748800165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2011

Frater C; Mackey D; Emmett L; Van der Wall H, 2011, 'CALARA - Compassionate ALARA', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S448 - S448, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2011

Frater C; Seccombe L; Chung S; Pearson M; Mackey D; Russo R; Emmett L, 2011, 'Glossopharyngeal breathing causes lung perfusion changes in Extreme Breath Hold Divers', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, pp. S458 - S459, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208619401833&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2006

Chung T; Connor D; Joseph J; Emmett L; Ma D; Kritharides L, 2006, 'Platelet activation, inflammation and cardiac dysfunction, and their relation to the extent of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 295 - 295, presented at 28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology, SPAIN, Barcelona, 02 September 2006 - 06 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240668402012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2006

Chung T; Emmett L; Kritharides L, 2006, 'Reduced tricuspid annular motion and right ventricular myocardial tissue velocities predict the extent and resolution of acute pulmonary embolism', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 616 - 616, presented at 28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology, SPAIN, Barcelona, 02 September 2006 - 06 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240668404188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2001

Emmett L; Husain M; Barolet A; Freeman M; Iwanochko RM, 2001, 'A reversible regional wall motion abnormality on single day exercise Tc-99m sestamibi gated SPECT perfusion: Imaging predicts a high grade angiographic stenosis.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 94P - 95P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168821900354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2000

Van der Wall H; Magee M; Emmett L; Bruce W, 2000, 'A new appraoch to the diagnosis of fat embolism.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 326P - 326P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000089892401309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1999

Van der Wall H; Magee M; Magnussen J; Emmett L; Frater C; Murray P, 1999, 'A novel view for the scintigraphic assessment of the elbow.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, pp. 194P - 194P, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000080105800785&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1998

Rivory LP; Clarke S; Bishop JF; O'Donnell A; Emmett L; Findlay M, 1998, 'Irinotecan (CPT-11): A preliminary investigation of the relationship between trough concentrations of the active metabolite, SN-38, and toxicity', in ANNALS OF ONCOLOGY, KLUWER ACADEMIC PUBL, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000074749600194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Research Support (ongoing and completed last 3 years only)

2018-2020: CI CINSW grant for Prostate cancer imaging, genomic and theranostics research $3.75m

2017-2019: AI CINSW grant: Computed tomography (CT) and positron emission tomography (PET)/CT surveillance imaging in asymptomatic Stage III melanoma patients - a prospective cohort study of clinical

benefit and economic implications $500k.

2014-2018: CI Gap2 Movember Grant for PROPS trial : International prospective imaging trial in BCR post RP with MRI, F18 FCH and Ga PSMA.$1.65m

2016-2018: CI Paul Ramsay Foundation Grant for Prospective Lu PSMA trial (completed and in submission) $500K.

2018-2020: AI ANZUP/PCFA/Movember grant $1.5m: TheraP phase II trial – prospective multisite randomized trial comparing LuPSMA vs Cabazitaxel.

2017-2019: CI: Noxopharm funding for prospective phase 1 dose escalation trial in LuPSMA + NOX66 (radiation sensitizer) $ 900K

C. Contribution to Science

Multiple prospective trials and publications in PSMA ligand imaging and therapy in Prostate cancer since 2014.

Modulation of PSMA expression by Androgen deprivation therapy (ADT): Serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade. Emmett L, Joshua A, Epstein R, Ho B, Nguyen Q, Cusick T,Hickey A, Hruby G, Kneebone A, Chalasani V, O’Neill G, Stricker P. SNMMI oral presentation June 2018.

Results of a prospective trial of Lu¹⁷⁷ DKFZ 617 PSMA therapy for metastatic castrate resistant prostate cancer : Imaging predictors of treatment response and patterns of progression. Louise Emmett^1,2,³, Megan Crumbaker, Bao Ho, Kathy Willowson, Peter Eu, Lalith Ratnayake, Richard Epstein, Ashley Blanksby, Lisa Horvath, Alex Guminski, Kate Mahon, Charlotte Yin, Phillip Stricker, Anthony M. Joshua. (currently in submission Eur Urol Oncol July 2018. Presented WFNMB April 2018)

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017).J Med Radiat Sci, 64(1), 52-60.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. van Leeuwen, P. J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q., & Stricker, P. D. (2017). BJU Int, 119(2), 209-215. doi:10.1111/bju.1354

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976.

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., & Woo, H. H. (2017). Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2017.23

Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Hruby, G., Eade, T., Kneebone, A., Emmett, L., Guo, L., Ho, B., . . . Kwong, C. (2017). Radiother Oncol, 122(1), 99-102.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., . . . Emmett, L. (2015). J Nucl Med, 56(8), 1185-1190.

Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., . . . Emmett, L. (2016). (68) BJU Int, 117(5), 732-739. doi:10.1111/bju.13397

Initial multicentre experience of 68 Gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. Siriwardana, A., Thompson, J., van Leeuwen, P. J., Doig, S., Kalsbeek, A., Emmett, L., . . . Stricker, P. (2017). BJU Int. doi:10.1111/bju.13919

Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., . . . Chiti, A. (2017). Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-017-3725-1

Fendler, W. P., Calais, J., Allen-Auerbach, M., Bluemel, C., Eberhardt, N., Emmett, L., . . . Eiber, M. (2017). 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. doi:10.2967/jnumed.117.190827

Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP.AJR Am J Roentgenol. 2018 Jun 27:1-9

Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.

Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.

Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET.

Byrne K, Eade T, Kneebone A, Guo L, Hsiao E, Schembri G, Kwong C, Hunter J, Emmett L, Hruby G.

Radiother Oncol. 2018 Feb;126(2):244-248. doi: 10.1016/j.radonc.2017.10.022. Epub 2017 Nov 10.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.

J Nucl Med. 2018 Jan;59(1):82-88

My Research Supervision

last supervised 2017

Follow

Dr Louise Emmett

A. Personal Statement

Research Support (ongoing and completed last 3 years only)

C. Contribution to Science